Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Nov 6, 2024
Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Inclusion Criteria in the MyPEAKTM-1 Phase 1b/2 Trial of TN-201 Gene Therapy
Read more at globenewswire.comNASDAQ:TNYA (10/23/2025, 11:48:03 AM)
1.7
0 (0%)
Find more stocks in the Stock Screener
